So-Young International Inc.
NASDAQ:SYMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $239.36M
- Beta
- 1.98
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.95
Volume 0.46M
Average 0.63M
SY EBITDA Margin
EBITDA as a percentage of revenue.
So-Young International Inc.NASDAQ: SY
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin holds steady near -11.8%
EBITDA Margin was -11.8% in Q1 FY2026, down 0.1 pp from a year earlier. On a trailing-twelve-month basis it was -12.3%, down 11.0 pp year over year. Over 3 fiscal years it narrowed by 9.1 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 2 analysts of -6.8% for the fiscal year ending Dec 2026, up from -12.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -11.8%+0.5 pp QoQ
- Last fiscal yearDec 2025
- -12.3%-9.7 pp YoY
- LTMMar 2026
- -12.3%-11.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -0.1 pp | +3.5 pp | +3.6 pp |
| 1 year | -9.7 pp | +5.5 pp | +15.2 pp |
| 3 years | -9.1 pp | +20.1 pp | +29.2 pp |
| 5 years | — | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -12.3%
- Year-over-year change
- -9.7pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -12.3% | -9.7pp |
| FY2024 | 2024-12-31 | -2.6% | -6.2pp |
| FY2023 | 2023-12-31 | 3.6% | +6.8pp |
| FY2022 | 2022-12-31 | -3.2% | -6.9pp |
| FY2021 | 2021-12-31 | 3.7% | — |
EBITDA Margin vs competitors
How SY compares with its peers on the latest reported figures
- SY's LTM Mar 2026 EBITDA Margin of -12.3% is the 5th highest of the 9 companies compared; the peer median is -12.9%.
- Its year-over-year change of -11.0 pp is the 6th highest of 8, against a peer median of -6.3 pp.
- Over three fiscal years its change of -9.1 pp compares with a peer median of -1.1 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 939.0% | — | — | |
| LTM Feb 2026 | 21.5% | +0.4 pp | -16.1 pp | |
| LTM Mar 2026 | 1.2% | -11.7 pp | -1.1 pp | |
| LTM Apr 2026 | -0.7% | -9.9 pp | -12.9 pp | |
| LTM Mar 2026 | -12.3% | -11.0 pp | -9.1 pp | |
| LTM Mar 2026 | -25.0% | +470.9 pp | +71883.1 pp | |
| LTM Mar 2026 | -81.4% | -6.3 pp | +87.8 pp | |
| LTM Mar 2026 | -94.5% | -30.2 pp | +72.1 pp | |
| LTM Mar 2026 | -105.1% | +22.1 pp | -58.4 pp | |
| FY2025 | — | — | — | |
NMRANeumora Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding SY) | -12.9% | -6.3 pp | -1.1 pp | |
Competitors are the stored peer set for SY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.69B | 1.26B | 1.5B | 1.47B | 1.48B |
| Cost of Revenue | 327.89M | 393.29M | 544.34M | 567.59M | 774.04M |
| Gross Profit | 1.36B | 864.58M | 953.69M | 899.11M | 707.86M |
| Gross Margin | 80.6% | 68.7% | 63.7% | 61.3% | 47.8% |
| Research & Development | 286.57M | 235.09M | 203.52M | 165.03M | 133.31M |
| Selling, General & Admin | 1.04B | 732.3M | 811.22M | 818.57M | 833.76M |
| Operating Expenses | 1.4B | 967.39M | 1.01B | 1.52B | 967.07M |
| Depreciation & Amortization | 30.08M | 47.09M | 46.09M | 46.09M | 57.21M |
| EBITDA | 63.39M | (39.99M) | 53.96M | (38.39M) | (182.19M) |
| EBITDA Margin | 3.7% | -3.2% | 3.6% | -2.6% | -12.3% |
| Operating Income | (32.57M) | (102.81M) | (61.05M) | (624.49M) | (259.21M) |
| Operating Margin | -1.9% | -8.2% | -4.1% | -42.6% | -17.5% |
| Interest Income | 19.33M | 28.88M | 48.84M | 46.51M | 24.6M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 16.17M | 15.73M | 68.92M | 36.41M | 19.8M |
| Income Before Tax | (16.41M) | (87.07M) | 7.87M | (588.09M) | (239.4M) |
| Pre-Tax Margin | -1.0% | -6.9% | 0.5% | -40.1% | -16.2% |
| Income Tax Expense | 21.23M | (20.97M) | (18.08M) | (905K) | (774.31K) |
| Net Income | (8.37M) | (65.55M) | 21.28M | (589.53M) | (235.7M) |
| Net Margin | -0.5% | -5.2% | 1.4% | -40.2% | -15.9% |
| EPS (Basic) | (0.06) | (0.48) | 0.16 | (4.40) | (1.78) |
| EPS (Diluted) | (0.06) | (0.48) | 0.16 | (4.39) | (1.78) |
| Weighted Avg Shares | 138.04M | 138.04M | 133.19M | 134.09M | 131.59M |
| Weighted Avg Shares (Diluted) | 138.04M | 138.04M | 131.91M | 134.16M | 131.59M |
So-Young International Inc.
NASDAQ:SY
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.